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Abstract
Background: Monocyte chemoattractant protein (CCL2/MCP-1) is a chemokine that attracts cells involved in the
immune/inflammatory response. As microglia are one of the main cell types sustaining inflammation in brain, we
proposed here to analyze the direct effects of MCP-1 on cultured primary microglia.
Methods: Primary microglia and neuronal cultures were obtained from neonatal and embryonic Wistar rats,
respectively. Microglia were incubated with different concentrations of recombinant MCP-1 and LPS. Cell
proliferation was quantified by measuring incorporation of bromodeoxyuridine (BrdU). Nitrite accumulation was
measured using the Griess assay. The expression and synthesis of different proteins was measured by RT-PCR and
ELISA. Cell death was quantified by measuring release of LDH into the culture medium.
Results: MCP-1 treatment (50 ng/ml, 24 h) did not induce morphological changes in microglial cultures. Protein
and mRNA levels of different cytokines were measured, showing that MCP-1 was not able to induce
proinflammatory cytokines (IL-1b, IL6, MIP-1a), either by itself or in combination with LPS. A similar lack of effect
was observed when measuring inducible nitric oxide synthase (NOS2) expression or accumulation of nitrites in the
culture media as a different indicator of microglial activation. MCP-1 was also unable to alter the expression of
different trophic factors that were reduced by LPS treatment. In order to explore the possible release of other
products by microglia and their potential neurotoxicity, neurons were co-cultured with microglia: no death of
neurons could be detected when treated with MCP-1. However, the presence of MCP-1 induced proliferation of
microglia, an effect opposite to that observed with LPS.
Conclusion: These data indicate that, while causing migration and proliferation of microglia, MCP-1 does not
appear to directly activate an inflammatory response in this cell type, and therefore, other factors may be necessary
to cause the changes that result in the neuronal damage commonly observed in situations where MCP-1 levels are
elevated.
Background
One of the first steps necessary for the development of
an inflammatory response is the attraction of certain
types of cells to the site of inflammation [1]. Multiple
factors are involved in this process; among them, che-
mokines constitute some of the main agents since they
are responsible for the creation of the concentration
gradient towards which leukocytes and other cells
migrate [2]. In agreement with this, the suppression of
chemokines, or of their activity, results in a concomitant
suspension of the inflammatory response [3].
An exaggerated inflammatory response can cause
damage to cells that are necessary for the correct func-
tioning of the tissue/organ they are part of. This is parti-
cularly important in brain, where damage to or loss of
constitutive cells can have worse consequences than in
different tissues with higher regenerative capacities. The
main immune cells in brain are microglia [4]; they con-
tinuously inspect their environment and react to
changes that could threaten homeostasis [5]. This reac-
tion can be detected mainly by changes in their mor-
phology as well as by their expression of different genes
or release of certain cytokines. The principal purpose of
this reaction appears to be protection of neurons and
their synapses [6,7]. However, neurons in the proximity
of activated microglia can be damaged by an
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exaggerated inflammatory response. Microglia can also
receive some signals that make them attack healthy neu-
rons as is the case in neurodegenerative diseases such as
Alzheimer’s disease, HIV-associated dementia or multi-
ple sclerosis, among others [8].
As a consequence of these facts, it becomes interesting
to elucidate the precise mechanisms regulating micro-
glial changes and to distinguish between those that have
potentially deleterious consequences and those that
result in protection against injuries. As surveillance
agents, microglia need to travel to the places where they
are needed, and chemokines regulate these movements
[9]. As the monocyte chemoattractant protein (CCL2/
MCP-1) is one of the main chemokines regulating
microglial movement, it was our goal to study here
some of the effects MCP-1 has on isolated microglia,
and to determine if the responses it provokes in micro-
glia may be responsible for the neuronal damage
observed in situations where microglia are attracted to
sites of inflammation by this chemokine. Different stu-
dies have shown that suppression of MCP-1 or of its
effects can be protective against different injuries or dis-
eases [10], and have suggested that this could be consid-
ered as a therapeutic strategy.
However, an alternative role of MCP-1 depicts a dif-
ferent scenario: MCP-1 has also been proven to protect
neurons against different stimuli [11-13], and recent stu-
dies have indicated that it could also have other func-
tions besides those that characterize it as a
chemoattractant [14-17].
Our experiments show that MCP-1 induces prolifera-
tion of isolated microglia, but we could not detect
changes in the production of proinflammatory cytokines
in microglia treated with similar concentrations of
MCP-1. Accordingly, MCP-1 did not induce morpholo-
gical changes in microglia nor did it induce expression
of the proinflammatory enzyme NOS2 or the accumula-
tion of nitrites, an indicator of the production of nitric
oxide caused by NOS2. Lipopolysaccharide (LPS) was
used as a positive control to cause those changes char-
acteristic of microglia that lead to the production of
neurotoxic factors. While LPS also reduced the expres-
sion of various neurotrophic factors, MCP-1 did not
modify them. All these data suggest that MCP-1 has
some effects on microglia which do not appear to be
directly toxic to neurons, at least at the concentrations
analyzed. However, microglia could be stimulated by
MCP-1 to generate certain factors which we did not
analyze or which we simply may not know about. In
order to further explore this possibility, microglia were
treated with MCP-1 while co-cultured with primary
neurons, and no neuronal damage was observed under
these conditions, further suggesting a lack of a change
in microglia that can be toxic to neurons.
The results presented here indicate that the changes
caused by MCP-1 in microglia may not be responsible
for the neuronal damage observed in certain situations
where MCP-1 expression is elevated, and support the




Fetal calf serum (< 10 EU endotoxin per mL), basal
medium Eagle, neurobasal medium (NBM), DMEM,
DMEM-F12 and the B27 without antioxidants supple-
ments for cell cultures were from GIBCO Life Technol-
ogies (Carlsbad, CA, USA). LPS from Escherichia coli
0111:B4 for cell treatments and glutamine, gentamicin,
penicillin and streptomycin for cell cultures were from
Sigma (St. Louis, MO, USA). Recombinant rat MCP-1
for cell treatments was from Peprotech (Rocky Hill, NJ,
USA). Trizol© for RNA isolation, Taq polymerase for
cDNA synthesis and cDNA synthesis reagents were
from Invitrogen (Carlsbad, CA, USA).
Microglial cultures
All experimental protocols followed the guidelines of the
Animal Welfare Committee of the Universidad Complu-
tense according to European legislation (2003/65/EC).
Rat cortical microglial cells were obtained as described
previously [18]. Briefly, 1-day-old Wistar rats (Harlan
Iberica) were used. Enriched cultures of microglia were
prepared from primary mixed cultures of rat cortical
glial cells, plated in T-75-cm2 flasks in DMEM contain-
ing 10% FCS and antibiotics (100 IU/ml penicillin and
100 mg/ml streptomycin; Sigma), and incubated at 37°C
in a humidified atmosphere containing 5% CO2. Briefly,
microglial cells were detached from the astrocyte mono-
layer by gentle shaking 11-13 days after the dissection.
The cells were plated at 4·105 cells/ml in 6.5 mm Trans-
well© inserts (100 μl/well), 24 (500 μl/well) or 96 (100
μl/well)-well plates. Under these conditions, the cultures
were 95-98% Mac-1 positive. All experiments were car-
ried out in 10% FCS/DMEM-F12.
Neuronal cultures
Primary cultures of cortical neurons were prepared as
described [19], with some modifications. Brains were
removed from fetal Wistar rats (Harlan Iberica) at
embryonic day 16, and the cortical area was dissected.
Neurons were mechanically dissociated in 80% basal
medium Eagle containing 33 mmol/L glucose, 2 mmol/L
glutamine, 16 mg/L gentamicin, 10% horse serum, and
10% fetal calf serum and plated at 1·106 cells/ml in
poly-L-lysine-precoated, 12, 24 or 96-multiwell plates.
The medium was replaced 24 h later with serum-free
NBM supplemented with 0.5 mmol/L glutamine and
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complete B27 without antioxidants to reduce glial con-
tamination and after 4 days 50% of the medium was
replaced with fresh NBM. Cultures consisted of 98 ± 2%
NeuN-positive cells. After 9 days in vitro, inserts (0.4
μm pore size) containing microglia in 10% FCS/DMEM-
F12 were placed over the neurons (this system allowed
for the transfer of material from one side of the mem-
brane to the other while preventing direct contact of
both cell cultures). 24 h later, the media in the inserts
were replaced by new ones containing different treat-
ments. After 24 h cell viability was assessed by LDH
measurements.
Nitrites Measurement
NO production was measured indirectly by nitrite
measurement in the cell culture media. An aliquot of
the cell culture media (80 μl) was mixed with 40 μl of
Griess reagent and the absorbance was measured at
550 nm.
Cell viability
Cell viability was assessed by measurement of released
lactate dehydrogenase (LDH), using the CytoTox-96 kit
from Promega (Madison, WI, USA) according to the
manufacturer’s instructions.
IL-1b Measurement
IL-1b levels in the incubation medium were detected
using a specific enzyme-linked immunosorbent assay
(ELISA) for rat IL-1b, carried out according to the man-
ufacturer’s instructions (R&D Systems, Inc.). Briefly, the
medium was collected from the microglial cells and
stored at -80°C until the day of the assay (avoiding
repeated freeze-thaw cycles). A standard curve was gen-
erated during each assay in the concentration range 0-
1,000 pg/ml using the rat IL-1b standard provided in
the kit. The minimum detectable dose of IL-1b was 5
pg/ml.
IL-6 Measurement
IL-6 levels in the incubation medium were detected
using a specific enzyme-linked immunosorbent assay
(ELISA) for rat IL-6, carried out according to the manu-
facturer’s instructions (BD Biosciences). Briefly, the
medium was collected from the microglial cells and
stored at -80°C until the day of the assay (avoiding
repeated freeze-thaw cycles). A standard curve was gen-
erated during each assay in the concentration range 0-
5,000 pg/ml using the rat IL-6 standard provided in the
kit. The assay detection limits were of 78-5000 pg/mL.
BrdU Incorporation Assay
DNA synthesis was measured using a bromodeoxyuri-
dine (BrdU) Cell Proliferation Kit (Calbiochem,
Darmstadt, Germany). BrdU labeling solution was added
to the cells in combination with the different treatments
and incubated for 24 h. After removal of the culture
medium, the cells were fixed, permeabilized and the
DNA denatured. Anti-BrdU antibody was then added
before the addition of the mouse IgG-peroxidase conju-
gate. The signal was developed with tetramethylbenzi-
dine solution in darkness. Absorbance in each well was
measured using a spectrophotometric plate reader at
450 nm with a reference wavelength at 595 nm.
mRNA analysis
Total cytoplasmic RNA was prepared from cells using
TRIZOL© reagent (Invitrogen); aliquots were converted
to cDNA using random hexamer primers. Quantitative
changes in mRNA levels were estimated by real time
PCR(Q-PCR) using the following cycling conditions: 35
cycles of denaturation at 95°C for 10 s, annealing at 58-
61°C for 15 s depending on the specific set of primers,
and extension at 72°C for 20 s. Reactions were carried
out in the presence of SYBR green (1:10000 dilution of
stock solution from Molecular Probes, Eugene, OR,
USA), carried out in a 20- μL reaction in a Corbett
Rotor-Gene (Corbett Research, Mortlake, NSW, Austra-
lia). The primers used for NOS2 were: forward: 5’-
AGCA ACA TTT GGC AAT GGAGAC TGC-3’ and
reverse: 5’-AGC AAA GGC ACA GAA CTG AGG
GTA-3’. The primers used for MIP1a were: forward: 5’-
CAG AAC ATT CCT GCC ACC TGC AAA-3’ and
reverse: 5’-AGG AAT GTG CCC TGA GGT CTT
TCA-3’. The primers used for Cyclin D1 were: forward:
5’-TGC TGC AAA TGG AAC TGC TTC TGG-3’ and
reverse: 5’-AAG GTC TGT GCA TGT TTG CGG
ATG-3’. The primers used for CDK4 were: forward: 5’-
ACG CCT GTG GAT ATG TGG AGT GTT-3’ and
reverse: 5’-AGT CGT CTT CTG GAG GCA ATC
CAA-3’. The primers used for PCNA were: forward: 5’-
AGC AAC TTG GAA TCC CAG AAC AGG-3’ and
reverse: 5’-TAA GGT CCC GGC ATA TAC GTG
CAA-3’. The primers used for IL1b were: forward: 5’-
ACC TGC TAG TGT GTG ATG TTC CCA-3’ and
reverse: 5’-AGG TGG AGA GCT TTC AGC TCA
CAT-3’. The primers used for IGF-1 were: forward: 5’-
CCG CTG AAG CCT ACA AAG TC-3’ and reverse: 5’-
GGA AAT GCC CAT CTC TGA AA-3’. The primers
used for bFGF were: forward: 5’-GAA CCG GTA CCT
GGC TAT GA-3’ and reverse: 5’-CCG TTT TGG ATC
CGA GTT TA-3’. The primers used for IL6 were: for-
ward: 5’-AAC TCC ATC TGC CCT TCA GGA ACA-3’
and reverse: 5’-AAG GCA GTG GCT GTC AAC AAC
ATC-3’. The primers used for GAPDH were: forward:
5’-TGC ACC ACC AAC TGC TTA GC-3 and reverse:
5’-GGC ATG GAC TGT GGT CAT GAG-3’. Relative
mRNA concentrations were calculated from the take-off
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point of reactions using included software, and GAPDH
levels were used to normalize data.
Cell morphology
Microglia morphology was analyzed by phase contrast
microscopy. Images were obtained on a Nikon Eclipse
Ti-S (Tokyo, Japan) microscope equipped with a Digital
Sight digital camera and NIS-Elements imaging software.
Statistical analysis
All experiments were done at least in triplicate. When
more than two experimental groups were present in the
same experiment, data were analyzed by one-way
ANOVA followed by Newman-Keuls multiple compari-
son tests and p values < 0.05 were considered signifi-
cant. When two experimental groups were present in
the same experiment, data were analyzed by unpaired t
tests, and p values < 0.05 were considered significant.
Results
MCP-1 induces microglia proliferation
A BrdU immunoassay was used to evaluate the prolif-
eration of microglia in response to MCP-1. Different
concentrations of MCP-1 (10-200 ng/ml) or LPS (0.1
μg/ml) were added to the culture medium and the cells
were incubated for 24 h in the presence of BrdU. After
this treatment, we could detect a higher degree of BrdU
incorporation in the microglia treated with MCP-1. The
changes were concentration-dependent up to the con-
centration of 50 ng/ml. On the other hand, LPS treat-
ment reduced microglia proliferation. (Figure 1)
Quantification of cell cycle-dependent transcripts
After observing MCP-1 alteration of microglia prolifera-
tion it became interesting to study if the expression of
different proteins involved in the regulation of the cell
cycle was also modulated by MCP-1. In accordingly with
what we observed in BrdU studies, LPS treatment caused
a reduction in mRNA levels of cyclin D1, cyclin-dependent
kinase 4 (CDK4) and proliferating cell nuclear antigen
(PCNA). On the other hand, MCP-1 elevated PCNA
mRNA indicating that this treatment induces microglia
proliferation. However, no modifications could be detected
by MCP-1 treatment of cyclin D1 or CDK4 (Figure 2).
Microglia activation
The induction of the enzyme NOS2 is considered to be
a marker of those microglial modifications that lead to
Figure 1 MCP-1 induces microglia proliferation. Microglia were
incubated for 24 h with fresh media (control), MCP-1 (10-200 ng/
ml) or LPS 0.1 μg/ml. Cell proliferation was assayed using a BrdU kit
as described in the Methods section. Data are expressed as
percentage of control values (set to 100%); ***p < 0.0001 versus
control, **p < 0.001 versus control, *p < 0.005 versus control. Data
are means ± SE of n = 12 replicates per group.
Figure 2 Expression of cell cycle proteins . Microglia were
incubated for 24 h with fresh media (control), LPS 0.1 μg/ml, MCP-1
50 ng/ml, or a combination of LPS and MCP-1 at the indicated
concentrations. RNA was isolated and cyclin D1 (A), CDK4 (B) and
PCNA (C) mRNA levels determined by RT-PCR. Data are expressed as
percentage of control values (set to 100%); **p < 0.001 versus
control, *p < 0.005 versus control, p < 0.005 versus LPS. Data are
means ± SE of n = 6 replicates per group.
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an inflammatory response. To study this possibility, we
treated microglia cultures with MCP-1 and measured
the concentration of nitrites present in the culture
media, as an indirect way to detect modifications of
NOS2 activity and the subsequent release of nitric
oxide. Under these conditions we could not detect mod-
ifications of nitrite concentration by MCP-1 treatment
(Figure 3A).
It was also interesting for us to analyze the possible
exacerbating effect of MCP-1 in the presence of a differ-
ent microglia-activating agent. An approach to this was
made by co-incubating the cells with different concen-
trations of LPS. We observed a small but significant
increase when MCP-1 was added to the higher concen-
tration of LPS used (Figure 3A); however we could not
detect similar differences in the other experiments
described below.
As a confirmation of the nitrite differences, mRNA
levels of NOS2 in microglia were measured by RT-PCR.
For this we chose the concentration of MCP-1 with the
highest proliferative effect. Under the conditions used
(50 ng/ml, 24 h), MCP-1 did not modify the expression
of NOS2, nor did it alter the induction caused by LPS
treatment (Figure 3B).
Morphological alterations of microglia are also a good
way to evaluate the effect of different agents on this
type of cell. Enlargement of the microglial cell body and
loss of ramifications, developing an amoeboid shape, are
commonly caused by LPS or other toxins [20]. While
those changes could be easily detected in LPS-treated
cells, no modifications in the appearance of MCP-1-
treated cells could be appreciated (Figure 3C).
Expression of inflammatory cytokines
Our main goal was to analyze if MCP-1 can provoke
some change in microglia that results in toxicity to
neurons. For this purpose we measured the expression
and synthesis of some pro-inflammatory cytokines
such as interleukin 1b (IL-1b) or interleukin 6 (IL-6)
as well as the chemokine macrophage inflammatory
Figure 3 Microglia activation. (A) Nitrite levels were measured in microglial media after 24 h incubation with fresh media (control), MCP-1 (10-
200 ng/ml), LPS (0.1, 1 μg/ml) or MCP-1 50 ng/ml in combination with LPS. Data are expressed as μM of nitrites and are expressed as mean ±
SE for n = 10 replicates per group. ***p < 0.0001 versus control, p < 0.005 versus LPS 1 μg/ml (a). (B) Microglia were incubated for 24 h with
fresh media (control), LPS 1 μg/ml, MCP-1 50 ng/ml or the combination of LPS and MCP-1 at the indicated concentrations. RNA was isolated
and NOS2 mRNA levels determined by RT-PCR. Data are expressed as percentage of control values (set to 100%); ***p < 0.0001 versus control.
Data are expressed as mean ± SE for n = 6 replicates per group. (C) Representative images corresponding to microglia incubated for 24 h with
fresh media (control), MCP-1 (50 ng/ml) or LPS 1 μg/ml. The images shown are representative of experiments done on three separate microglial
preparations.
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protein 1 alpha (MIP-1a). MCP-1 alone or in combi-
nation with LPS was added to microglia cultures and
the cells were incubated for 24 h. After this, mRNA
was isolated and analyzed by RT-PCR. MCP-1 caused
no significant changes in any of the cytokines studied,
nor did it alter the elevations caused by LPS (Figure
4A). Release of IL-1b and IL-6 into the culture media
was also measured by ELISA and no modification
could be detected as a result of MCP-1 treatment (Fig-
ure 4B).
Neuronal toxicity
Since we could not observe modification by MCP-1 of
any of the characteristic activation markers evaluated,
we decided to analyze the direct effect of MCP-1-treated
microglia on neurons. Primary cortical neurons were
cultured for 9 days. At this point, microglia inserts were
placed over the neurons. As previously described, MCP-
1 was added to microglial cultures alone or in combina-
tion with LPS, and 24 h later LDH levels were measured
in the neuronal culture media. While the addition of
LPS to microglial cultures caused neuronal death, MCP-
1 did not affect the viability of the neurons nor did it
alter LPS effects (Figure 5).
The direct effect of LPS on neurons was evaluated by
treating inserts without microglia in the same conditions
as those containing microglia. This procedure did not
result in significant alterations of neuronal LDH.
Production of trophic factors
Since MCP-1 does not appear to induce production of
potentially neurotoxic agents such as nitric oxide or
proinflammatory cytokines, it could cause harmful
effects by reducing the production of trophic factors.
mRNA levels for basic fibroblast growth factor (FGF)
and insulin-like growth factor 1 (IGF) were measured by
RT-PCR in microglia treated with MCP-1 alone or in
combination with LPS for 24 h. Under these conditions,
LPS treatment caused a great reduction in the produc-
tion of both proteins’ mRNAs while MCP-1 did not
cause any modification for FGF (Figure 6A) and caused
an increase for IGF (Figure 6B).
Figure 4 Expression of pro-inflammatory cytokines. (A) Microglia were incubated for 24 h with fresh media (control), LPS 1 μg/ml, MCP-1 50
ng/ml or a combination of LPS and MCP-1 at the indicated concentrations. RNA was isolated and MIP-1a, IL-1b and IL6 mRNA levels
determined by RT-PCR. Data are expressed as percentage of control values (set to 100%); ***p < 0.0001 versus control. Data are expressed as
mean ± SE for n = 6 replicates per group. (B) Microglia were incubated for 24 h with fresh media (control), LPS 1 μg/ml, MCP-1 50 ng/ml or a
combination of LPS and MCP-1 at the indicated concentrations. IL-1b and IL-6 levels in the media were assessed by ELISA. ***p < 0.0001 versus
control. Data are expressed as mean ± SE for n = 10 replicates per group.
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Discussion
The data presented here analyze microglial activation as
a consequence of MCP-1 treatment. While no morpho-
logical changes or production of inflammatory mediators
could be detected, we found that MCP-1 stimulates the
formation of new microglia. This suggests that MCP-1
could elevate microglia concentrations by attracting
these cells and also by facilitating their proliferation, but
it would not be associated with their activation or with
the generation of neurotoxic agents.
Since MCP-1 activity can be modified by plasmin or
matrix metalloproteinases [21,22], we cannot discard the
possibility that such modification is a requirement for
MCP-1 to exert the effects observed.
After its discovery as a chemokine, and particularly over
the last few years, MCP-1 has proven to be a key mediator
in different processes. Some of them are related to its abil-
ity to attract cells, such as directing the migration of
neural progenitors [23], while others seem to be indepen-
dent of its chemoattractant abilities and suggest that
MCP-1 may also participate as a modulator of neuronal
communication [14,24], neuronal regeneration [15], angio-
genesis, hematopoiesis [25] or immunoregulation [16].
Besides these different roles of MCP-1, there are sev-
eral studies focused on its involvement in neuro-inflam-
matory reactions [26]. Since MCP-1 attracts those cells
necessary for the development of an inflammatory
response, the blockade of this attraction would reduce
inflammation and all the changes associated to it. How-
ever, inhibition of MCP-1 production or of its activity
should be carefully considered as a therapeutic target,
mainly because some of its actions could be necessary
for homeostasis maintenance or simply remain yet
unknown. Based on this, we sought here to elucidate, at
least in part, if MCP-1 can directly cause activation of
the main immune cells in brain, and if this could contri-
bute to the death of neurons.
While MCP-1’s ability to attract leukocytes [27] and
other types of cells such as microglia [12] is well known,
its proliferative effect on microglia has not been so
intensely investigated. Studies performed on human
astrocyte cultures have also shown the ability of MCP-1
to induce proliferation of these cells [28], but to our
knowledge this is the first study to describe the induc-
tion of microglia proliferation by MCP-1.
Figure 5 Neuronal toxicity. Microglia plated on transwell
membranes were transferred to wells containing primary neurons.
After 24 h, the microglia were treated for a further 24 h with fresh
media (none), LPS 1 μg/ml, MCP-1 50 ng/ml or a combination of
LPS and MCP-1 at the indicated concentrations. After treatment,
inserts were removed and cell viability was assessed by
measurement of LDH in the neuronal media. Inserts without
microglia were treated with LPS (LPSn) under the same conditions
as those described above for microglia. Data are expressed as
percentage of control values (set to 100%); ***p < 0.0001 versus
control. Data are expressed as mean ± SE for n = 12 replicates per
group.
Figure 6 Production of trophic factors. Microglia were incubated for 24 h with fresh media (control), LPS 1 μg/ml, MCP-1 50 ng/ml or a
combination of LPS and MCP-1 at the indicated concentrations. RNA was isolated and bFGF (A) and IGF-I (B) mRNA levels determined by RT-
PCR. Data are expressed as percentage of control values (set to 100%); ***p < 0.0001 versus control. Data are expressed as mean ± SE for n = 6
replicates per group.
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We tested the effects of different concentrations of
MCP-1 on nitrite production and no modification was
observed for any concentration. A concentration of 50
ng/ml was the lowest one of those tested to induce the
maximal degree of proliferation detected. Based on this
we chose that concentration for further experiments. At
similar concentrations we had previously observed
MCP-1 to cause protective changes in neuronal cultures
[29].
The morphology of the cells, together with the mea-
surements of MIP-1a, IL-1b, IL-6 and NOS2 expres-
sions and synthesis indicates that MCP-1 under the
conditions used does not induce pro-inflammatory
changes in microglia.
Other authors have reported that MCP-1 induces pro-
duction of IL-1b and TNFa in mice microglial cultures
as well as death of neurons exposed to MCP-1-activated
microglia [30]. However, we could not observe similar
effects in our cultures. This may be due to inter-species
differences or to some other unidentified factors we are
not yet aware of. Further experimentation may help us
to identify the source of this dissimilarity.
Also, certain in vivo studies have shown that MCP-1
activates spinal microglial cells [31] and that MCP-1
blockade may reduce microglial activation [32]. But due
to the nature of the experimental models used in these
studies, where microglia are not isolated, we cannot
conclude that MCP-1 by itself causes activation of
microglia. The use of cultures, despite all its disadvan-
tages (i.e. isolation of cells from their natural environ-
ment) provides a better way to analyze the direct effect
of any agent on a particular type of cell. This was pre-
cisely our goal: to study the direct effect of MCP-1 on
microglia in the absence of other cells that might also
affect microglial behaviour.
The situation could be explained in a simplistic way
by considering that MCP-1 may attract microglia (and
maybe induce their proliferation), but other factors
could be responsible for their activation. Furthermore,
the attraction of microglia could help healing injuries
through transformation of these cells into other cell
types [33].
It was of particular interest for us to find that LPS had
an effect opposite to that of MCP-1, reducing the prolif-
eration of microglia. Other groups have described no
proliferative effect of LPS or a reduction of proliferation
when combined with IFNg [34,35]. These changes have
been classified by some authors as a resemblance of a
chronic activation of microglia [36] which leads to the
degeneration of these cells and a subsequent loss of the
support they provide for neurons that will also even-
tually result in neuronal death.
This is in agreement with the reduction in expres-
sion of the trophic factors FGF and IGF that we could
detect as a result of LPS treatment of microglia.
Microglia have previously been shown to be a source
of FGF [37] and IGF [38]. FGF stimulates neurite out-
growth of different types of neurons and supports their
survival [39,40] while IGF also is known to protect
neurons and to promote proliferation of neuronal pro-
genitors [41] as well as glial cells [42,43]. Interestingly,
we detected an increase of IGF mRNA after treating
microglia with MCP-1. IGF has also been proposed as
a mediator of the protection MCP-1 provides for ret-
inal ganglion cells in an experimental glaucoma model
[44]. In this study [44], the authors showed that while
elevated concentrations of MCP-1 can be neurotoxic,
lower ones have the opposite effect. They also indi-
cated how, in the absence of glial cells, neuroprotective
actions of MCP-1 are not observed, suggesting that
these cells may help MCP-1 to protect neurons. In
according with this idea, the proliferation of microglia
that we describe here would facilitate MCP-1’s neuro-
protective potential. This offers the possibility to
explore this event in vivo, and to analyze if there are
any differences between resident and bone marrow-
derived microglia, since MCP-1 acts on both of these
types of cells [45].
Altogether, we can hypothesise that MCP-1, like many
other regulators of brain cell function, may exert a
maintenance role in the CNS at constitutive concentra-
tions; however, as a result of certain disturbances, its
production can be altered leading to different changes,
some of which could have deleterious consequences.
As mentioned above, our co-culture model allowed us
to test the possible consequences of microglial exposure
to MCP-1 on neurons. This study confirmed the infor-
mation obtained from the cytokine measurements, sug-
gesting that MCP-1 does not appear to cause microglial
modifications that can damage neurons.
Our previous studies have demonstrated induction of
MCP-1 in astrocytes by the neurotransmitter noradrena-
line (NA) [29]. Our interest on NA is based on its anti-
inflammatory effects, which have been confirmed by
both in vivo [46,47] and in vitro [19,48] studies. These
effects help protect neurons against different injuries,
and reduction of NA levels in brain seems to facilitate
the progression of certain neurodegenerative diseases
such as Alzheimer’s [49] and Parkinson’s diseases [50].
Recently, a role for NA in the progression of multiple
sclerosis has also been described [51].
After finding that NA causes a large production of
MCP-1 in astrocytes, it seemed reasonable to consider
MCP-1 as a mediator of some noradrenergic effects. In
fact we could demonstrate that noradrenaline induction
of MCP-1 in astrocytes can protect neurons against
excitotoxic damage [29]. Other authors have also
described MCP-1 as a neuroprotective agent against
Hinojosa et al. Journal of Neuroinflammation 2011, 8:77
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excitotoxicity [11,13] or in neurodegenerative diseases
such as Alzheimer’s disease [12].
Conclusions
In summary, the goal of this study was to analyze the
possible involvement of MCP-1 in the neuronal damage
observed in certain situations where an inflammatory
response takes place, and particularly, if this is mediated
by the activation of microglia. Our results indicate that
direct incubation of MCP-1 with cultured microglia sti-
mulates microglial proliferation but it does not appear
to cause modifications that interfere with neuronal via-
bility. According to this, inhibition of MCP-1 as a way
to protect neurons in certain pathologies should be
carefully considered. This chemokine may not be
directly responsible for the neuronal damage character-
istic of those situations, and control of its function may
interfere with other pathways it regulates.
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